Domagrozumab (PF-06252616) (INN) is a humanized monoclonal antibody designed for the treatment of Duchenne muscular dystrophy.
[1][2] This drug was developed by Pfizer.
Pfizer stopped development in 2018 after disappointing results in 2 human trials.
[3] This monoclonal antibody–related article is a stub.
You can help Wikipedia by expanding it.